Kynmobi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for acute, intermittent treatment of “off” episodes in people with Parkinson’s disease. Kynmobi is also referred to by its drug name, Apomorphine HCl.
Kynmobi is a nonergoline dopamine agonist. Kynmobi is believed to work by imitating the action of dopamine in the brain.
How do I take it?
Kynmobi is taken sublingually (under the tongue) as needed, up to five times a day.
Kynmobi is available as a sublingual film.
The FDA-approved label for Kynmobi lists common side effects including nausea, swelling and pain in the mouth and throat, dizziness, and sleepiness.
Rare but serious side effects listed for Kynmobi include falls, fetal toxicity, hallucinations, impulsive behaviors, and heart problems.
For more details about this treatment, visit:
Kynmobi — Sunovion Pharmaceuticals
We never share your personal information with anyone.
Want to stay up to date on the latest news and articles about Parkinson's disease?